Alkem Laboratories Ltd

Alkem Lab Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Alkem Laboratories Ltd

₹ 4,961 0.85%
03 Jul 10:41 a.m.
alkemlabs.com BSE: 539523 NSE: ALKEM
About

Alkem Laboratories is engaged in pharmaceutical business with global operations. The Company is engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products.(Source : 202003-01 Annual Report Page No:107)

Key Points

Leading Pharmaceutical company[1] Alkem is the fifth largest player in domestic formulation market with a market share of 3.9% as on March 31, 2022.
It has established its leadership position in acute therapy, with a strong market position in anti-infective, gastrointestinal, pain management, vitamins, minerals, and nutrient segments.

Website BSE NSE
  • Market Cap ₹ 59,320 Cr.
  • Current Price ₹ 4,961
  • High / Low ₹ 5,581 / 3,440
  • Stock P/E 33.0
  • Book Value ₹ 883
  • Dividend Yield 0.81 %
  • ROCE 18.3 %
  • ROE 18.1 %
  • Face Value ₹ 2.00
Edit ratios

Pros

  • Company has been maintaining a healthy dividend payout of 35.5%

Cons

  • The company has delivered a poor sales growth of 11.3% over past five years.
  • Tax rate seems low
  • Promoter holding has decreased over last 3 years: -3.42%
  • Working capital days have increased from 128 days to 181 days

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024
1,917 2,279 2,364 2,181 2,006 2,058 2,461 2,297 2,238 2,253 2,635 2,495 2,365
1,501 1,728 1,776 1,709 1,807 1,875 2,056 1,841 1,906 1,919 1,980 1,925 1,958
Operating Profit 416 551 588 472 200 183 406 456 332 334 655 569 408
OPM % 22% 24% 25% 22% 10% 9% 16% 20% 15% 15% 25% 23% 17%
36 39 43 63 54 55 74 61 77 65 62 44 71
Interest 7 9 8 7 13 22 20 23 22 21 19 21 21
Depreciation 49 52 54 58 55 57 58 58 57 58 59 58 69
Profit before tax 396 529 569 470 186 160 402 436 330 319 639 534 389
Tax % 8% 11% 2% 7% 59% 12% 13% 11% 23% 15% -1% 6% 16%
363 469 558 437 77 140 351 389 255 271 647 504 325
EPS in Rs 30.34 39.25 46.67 36.56 6.43 11.72 29.33 32.53 21.31 22.70 54.07 42.17 27.18
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
2,291 2,660 3,072 3,911 4,548 5,281 5,714 6,677 7,220 8,830 9,055 9,748
1,860 2,261 2,722 3,180 3,668 4,308 4,667 5,209 5,268 7,018 7,665 7,783
Operating Profit 432 399 350 731 880 973 1,048 1,468 1,951 1,812 1,389 1,965
OPM % 19% 15% 11% 19% 19% 18% 18% 22% 27% 21% 15% 20%
166 164 177 240 115 101 66 96 175 199 254 242
Interest 79 84 73 59 24 32 28 39 43 38 86 82
Depreciation 36 43 60 74 76 108 141 187 199 219 230 244
Profit before tax 482 436 395 839 894 934 944 1,338 1,884 1,753 1,327 1,881
Tax % 3% -1% 7% 17% 1% 23% 15% 6% 11% 12% 15% 7%
467 440 368 700 883 716 800 1,264 1,685 1,541 1,134 1,747
EPS in Rs 390.40 368.17 30.75 58.56 73.86 59.87 66.90 105.75 140.93 128.90 94.88 146.13
Dividend Payout % 5% 5% 13% 22% 20% 22% 24% 24% 21% 26% 53% 27%
Compounded Sales Growth
10 Years: 14%
5 Years: 11%
3 Years: 11%
TTM: 8%
Compounded Profit Growth
10 Years: 15%
5 Years: 18%
3 Years: 3%
TTM: 57%
Stock Price CAGR
10 Years: %
5 Years: 23%
3 Years: 15%
1 Year: 41%
Return on Equity
10 Years: 18%
5 Years: 19%
3 Years: 16%
Last Year: 18%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity Capital 12 12 24 24 24 24 24 24 24 24 24 24
Reserves 2,291 2,703 3,077 3,576 4,369 4,861 5,441 6,257 7,602 8,720 9,326 10,531
1,229 947 1,103 380 368 548 503 1,209 1,384 2,294 1,182 1,037
479 540 657 843 1,137 1,381 1,324 1,616 1,763 2,132 2,200 2,447
Total Liabilities 4,011 4,202 4,861 4,822 5,898 6,814 7,292 9,106 10,773 13,169 12,731 14,038
832 909 870 875 1,126 1,471 1,606 1,837 1,758 1,882 1,825 1,823
CWIP 0 0 96 147 218 299 382 314 323 232 229 50
Investments 579 940 1,071 1,158 1,518 1,544 1,696 1,956 2,152 2,529 3,006 2,829
2,600 2,352 2,824 2,644 3,037 3,500 3,609 4,999 6,539 8,526 7,672 9,336
Total Assets 4,011 4,202 4,861 4,822 5,898 6,814 7,292 9,106 10,773 13,169 12,731 14,038

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
97 264 242 630 499 318 745 682 1,324 1,299 1,437 1,687
-349 119 -260 311 -362 -273 -313 -995 -1,121 -1,669 197 -866
274 -395 26 -958 -125 -60 -276 173 -209 437 -1,711 -959
Net Cash Flow 21 -12 8 -17 13 -15 156 -141 -5 67 -77 -138

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Debtor Days 46 40 45 45 51 60 62 85 79 73 71 66
Inventory Days 183 161 143 139 175 180 159 156 207 202 164 177
Days Payable 103 88 90 110 139 144 121 116 131 114 103 151
Cash Conversion Cycle 127 113 97 74 86 97 100 125 155 162 133 92
Working Capital Days 90 68 63 45 59 81 82 105 113 106 96 181
ROCE % 18% 15% 11% 22% 21% 19% 17% 20% 23% 18% 13%

Shareholding Pattern

Numbers in percentages

5 Recently
Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024
58.84% 58.84% 57.13% 57.13% 57.14% 57.16% 57.16% 57.16% 57.16% 56.74% 56.74% 56.74%
4.50% 5.33% 5.40% 5.41% 5.67% 4.46% 4.41% 4.44% 5.63% 6.03% 8.49% 9.11%
14.49% 13.99% 13.94% 14.14% 14.10% 15.73% 16.44% 16.69% 16.34% 17.63% 15.91% 15.63%
22.17% 21.84% 23.53% 23.32% 23.09% 22.65% 21.99% 21.69% 20.85% 19.58% 18.86% 18.51%
No. of Shareholders 93,54087,39286,88181,86984,10479,72176,51673,44066,79069,44265,18465,830

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

DRHP

Credit ratings

Concalls